ISV Member Newsletter March 2026

Download PDF

These first two months have been busy being submerged into the whirlwind of happenings and activities within our Society. As I am catching my breath, I concluded that we face challenges, but I also see real opportunities ahead. With our ever-growing number of enthusiastic and energetic volunteers we will succeed!

Anna Taliadoros - who many of you have met either in Seoul or in Stellenbosch - accepted a wonderful position as Head of Projects at the Centre for Economic Policy Research in London starting March 1, 2026. Luckily, we had already on-boarded ADS Insight as our 2026 Conference organizer. Together with Anna and Ted Gibson they were able to launch the website for the annual congress (www.isvcongress.org) and announce the applications for travel awards. If you are interested in applying, note that the deadline for those applications is approaching soon!

I am very excited that Denise Doolan (President-Emeritus) was elected by the Board to support the executive committee and myself as **Vice-Chair** of the Board. In this role she will continue to attend our monthly Officers meeting, be able to share her experience, and assist in the continued growth of our vibrant community.

There is a lot of excitement around the upcoming **in-person Congress** that will take place in Antwerp, Belgium (October 12 -14). Stanley Plotkin nominated ISV Fellow Alan Barrett to provide this years' **Plotkin lecture** and many other distinguished speakers have already committed to speak at the conference thanks to chair Michael Schotsaert, his co-chairs Lakshmi Krishnan and Isabel Leroux-Roels and the Scientific Committee. You can visit the Congress site for regular updates on matters related to the Congress.

A few words on our monthly seminar series that generally take place on the 2nd Wednesday of each month and are organized by former ISV President Ted Ross. Shan Lu's February 11th seminar on HIV vaccine development was elegantly moderated by Jeffrey Ulmer and drew many participants with a lively discussion. On March 11 our President-elect Indresh Srivastava spoke about the future of thermostable vaccines. He described the use of genetic engineering to create a thermostable influenza hemagglutinin H3 protein and touched on lyophilization and various microneedle patches as alternative strategies. His talk was followed by an engaging Q &A. On April 8th our 2025 Fellow Baik-Lin Seong will be presenting on Harnessing Chaperones in AI/Structure-Based Vaccine Design.

The NextGen seminars that generally feature two speakers are well attended and are reviewed elsewhere in this Newsletter. Continue to check out our event calendar on the ISV website for details on these seminars. ISV Events

I am really excited about the success of our mini symposium series that continues to attract hundreds of participants from industry and academic institutions. The 2nd mini-symposium on April 23rd will spotlight **AI and Clinical development** within the Vaccine space. Corey Fang (AstraZeneca) assembled an excellent panel of speakers: Kumar Singh Saikatendu (Novavax), Thomas Trolle (Evaxion), Federico Fantone (AstraZeneca) and Guilhem Richard (EpiVax).

The mentorship program spearheaded by Linda Lua is off to a flying start and in this Newsletter, you will find a spot-light on her and read about the program.

Our work would not be possible without the support of many sponsors, partners, and donors. We are excited to use this Newsletter to introduce them to our members. Below you can read what **GPN Vaccines** is all about in our inaugural **Vaccine Vanguard** feature.

We are planning to replace the Vaccine NewsFlash with **Vaccine Impact Stories**. These may include stories that emphasize the importance of vaccines from organizations like March of Dimes, Families fighting Flu, or from individuals. In this issue I will open this series by sharing why I became interested in vaccines and invite you to submit your topic of interest for future issues.

For questions, suggestions or concerns please do not hesitate to reach out to me at manoncox@isv-online.org.

ISV SPOTLIGHT

Linda Lua

Chair, ISV Mentorship Committee
Professor Emeritus, The University of Queensland
Director, The Growth Impact Pty Ltd, Australia

Linda is the Director of The Growth Impact Pty Ltd and Professor Emerita at The University of Queensland. She currently works as a biotechnology consultant and executive coach, bringing together her two passions to help individuals and organizations unlock their potential for innovation. Deeply committed to improving the accessibility and affordability of drugs, vaccines, and diagnostics, Linda is driven by the goal of ensuring that health technologies reach those who need them most. She places people at the center of her work and takes great satisfaction in supporting the development of future leaders.

Linda's leadership philosophy has been shaped through years of practical experience. Today, she works with biotechnology professionals and organizations to navigate complex leadership challenges and build the capabilities needed for impact. She believes leadership development must begin early as leaders are shaped over time, not overnight. As Linda explains: "*If we want an ecosystem where future leaders can thrive during challenging times and make meaningful decisions that advance technology, we must intentionally create environments for growth and model effective leadership behaviors*."

This philosophy has guided Linda in shaping the ISV Mentorship Program 2026, a platform designed to connect experienced leaders with emerging scientists in vaccinology. The program has launched with eleven mentor–mentee pairs embarking on a 12-month journey of co-learning and professional growth. Many leaders value the opportunity to give back to their community, and mentorship provides a powerful way to support the next generation. Together, we can help shape the development of future leaders.

If you are interested in joining Linda and others in making a difference in the vaccinology community, please reach out at mentorship@isv-online.org.

Errata: Januray 2026 ISV Newsletter Spotlight: Indresh Srivastava Vice President of Process and Formulation Development at ~~Moderna~~ Novavax

REMINDER!

LMIC and NON-LMIC Award Application Deadline:

31 MARCH 2026

Don't forget to submit your award application to the 2026 ISV Annual Congress.

This year, in order to submit your award application, you must create a Congress User Profile. All your submissions will be managed through this profile. Please click below or visit website to create your profile.

Create Congress User Profile

Once your user profile is created you may submit for the following award tracks:

- Non-LMIC PhD/ECR Award abstract submission
- LMIC PhD/ECR Award abstract submission

As a reminder, The 2026 ISV Annual Congress will be held from **October 12-14** at **A Room with a Zoo Elisabeth Center Antwerp** and co-chaired by Michael Schotsaert (Icahn School of Medicine at Mount Sinai, USA), Lakshmi Krishnan (National Research Council, Canada), and Isabel Leroux-Roels (University of Ghent, Belgium).

Please visit (https://isv-online.org/congress/2026-congress/) for all Congress related information. Please be sure to check in routinely as we will be continually updating the site with pertinent Congress information.

Please be sure to review and follow below guidelines for your abstract submissions or your award application.

Guidelines:

Non-LMIC Award Guidelines
LMIC Award Guidelines

Please contact Annick Hauchart Mannaerts via a.mannaerts@ads-insight.com if you have any questions concerning submissions.

Start VISA Applications Now!

(can take up to 5-6 months)

Click below links for further information:

General Explanation

Guide to Obtain a Visa C

VACCINE VANGUARD

GPN Vaccines Inc. ("GPN") is a clinical-stage biotechnology company dedicated to developing innovative vaccines against the world's most serious and prevalent pathogens. The Company's lead candidate, Gamma-PN, is engineered to address the critical shortcomings of currently licensed pneumococcal vaccines. By utilizing a sophisticated broad-spectrum approach, Gamma-PN aims to provide comprehensive protection against more than 100 known serotypes of the pneumococcus, representing a paradigm shift in preventative medicine.

Over the past 12 months, GPN has successfully completed its third Phase 1/2a clinical trial of Gamma-PN, yielding results that hold enormous promise for global health. Clinical data indicates that sera from participants vaccinated with Gamma-PN produce potent, functional antibodies capable of killing a wide diversity of pneumococcal strains. Crucially, these include several serotypes not covered by any currently licensed vaccines, as well as the notoriously difficult serotype 3, for which existing immunizations offer no effective protection.

In 2025, the company redomiciled to the United States and acquired BacVax Inc., which now operates as a wholly owned subsidiary. This acquisition provides a footprint in the United States and significantly expands upon GPN's intellectual property portfolio and pipeline of next-generation vaccines. Regulatory engagement has been consistently positive, with a Type C meeting with the FDA scheduled for mid-2026. This serves as a precursor to a full Investigational New Drug (IND) application in Q1 2027, which will be executed in parallel with a $100M pre-IPO funding round to fuel late-stage development.

"Our recent clinical milestones and the acquisition of BacVax mark a transformative era for GPN," said Dr. Tim Hirst, Chief Executive Officer and Chairman. "As we prepare for our public offering and late-stage trials, our focus remains on delivering a solution that is both scientifically superior and globally accessible".

GPN is guided by a world-class team of executives, board members, and advisors. The recent appointment of Dr. Bruce Forrest as Chief Scientific Officer and Board Member reinforces this excellence. Having previously led the clinical development of Pfizer's Prevnar program, Dr. Forrest possesses a first-hand understanding of the current market's limitations.

GPN Vaccines is therefore poised to redefine global immunization standards by advancing vaccine candidates that overcome the critical limitations of existing blockbuster vaccines.

For more information, please visit gpnvaccines.com.

VACCINE IMPACT STORY

Manon Cox

ISV President, 2026-2027
CEO, NextWaveBio

My personal story of how I became interested in Vaccine is extracted from a Portrait I wrote for **Human Vaccines & Immunotherapeutics**:

"After graduating from the University of Nijmegen (the Netherlands), I landed my first "job" at the University of Amsterdam in the late 1980s exploring the usefulness of PCR-based human papilloma virus (HPV) screening for early detection of cervical cancer. The work I did was boring, but important, as our findings from analyzing 3,000 cervical scrape specimens supported the hypothesis that HPV 16 and 18 were associated with early stage cervical cancer. Luckily, we only found those viruses in approximately 0.5% of the samples analyzed – a striking difference with incidence numbers now (30 years later) that report the virus being present in close to 50% of young women. The good news is that there are two modern vaccines for the prevention of cervical cancer on the market today."

"During this time I traveled to Africa and was confronted with the dramatic effects of the Human Immunodeficiency Virus (HIV/AIDS) throughout small villages in East Africa. Entire populations between the ages of 15 and 40 years old were wiped out in some of the places we visited. It was evident that we desperately needed a vaccine as that would be the only way to take control of the devastating impact of the disease caused by this virus. Unfortunately, more than 25 years later we still haven't made much progress."

(Authors Note: This article was written in 2015! And as we learned from Shan Lu's February 2026 seminar much still needs to be done)

You can read the full story in Human Vaccines & Immunotherapeutics

ESACT VACCINE TECHNOLOGY COURSE

Applications Now Open!

Applications are now open for the Vaccine Technology Course hosted by the European Society for Animal Cell Technology. This course provides in-depth training in modern vaccine development, with a focus on bioprocessing, manufacturing technologies, and translational considerations that bridge research and scalable production.

Designed for scientists and professionals working across academia and industry, the course offers participants an opportunity to deepen their understanding of vaccine platform technologies, process development, and regulatory perspectives in a highly interactive learning environment.

Importantly, at least eight grants are available to support participation, making this an excellent opportunity for trainees and early-career researchers to engage with leaders in the field.

For full course details, eligibility criteria, and application information, please visit:

https://esact.org/courses/vaccine-technology-course/

We encourage ISV members to share this opportunity widely and consider applying!

2025 ISV PAPER OF THE YEAR

The ISV Board Members and Fellows review vaccine literature published in 2025 and nominate papers for consideration. Board Members and Fellows then vote on the nominated papers and the paper receiving the majority of votes is selected as the paper of the year. The lead author will be invited to present the research at the Annual Congress. This process resulted in the selection of the following paper:

A natural experiment on the effect of herpes zoster vaccination on dementia

Nature. 2025 May;641(8062):438-446. doi: 10.1038/s41586-025-08800-x. Epub 2025 Apr 2. PMID: 40175543; PMCID: PMC12058522.

Authors
Eyting M, Xie M, Michalik F, Heß S, Chung S, Geldsetzer P.

Abstract
Neurotropic herpesviruses may be implicated in the development of dementia[1,2,3,4,5]. Moreover, vaccines may have important off-target immunological effects[6,7,8,9]. Here we aim to determine the effect of live-attenuated herpes zoster vaccination on the occurrence of dementia diagnoses. To provide causal as opposed to correlational evidence, we take advantage of the fact that, in Wales, eligibility for the zoster vaccine was determined on the basis of an individual's exact date of birth. Those born before 2 September 1933 were ineligible and remained ineligible for life, whereas those born on or after 2 September 1933 were eligible for at least 1 year to receive the vaccine. Using large-scale electronic health record data, we first show that the percentage of adults who received the vaccine increased from 0.01% among patients who were merely 1 week too old to be eligible, to 47.2% among those who were just 1 week younger. Apart from this large difference in the probability of ever receiving the zoster vaccine, individuals born just 1 week before 2 September 1933 are unlikely to differ systematically from those born 1 week later. Using these comparison groups in a regression discontinuity design, we show that receiving the zoster vaccine reduced the probability of a new dementia diagnosis over a follow-up period of 7 years by 3.5 percentage points (95% confidence interval (CI) = 0.6–7.1, $P = 0.019$), corresponding to a 20.0% (95% CI = 6.5–33.4) relative reduction. This protective effect was stronger among women than men. We successfully confirm our findings in a different population (England and Wales's combined population), with a different type of data (death certificates) and using an outcome (deaths with dementia as primary cause) that is closely related to dementia, but less reliant on a timely diagnosis of dementia by the healthcare system[10]. Through the use of a unique natural experiment, this study provides evidence of a dementia-preventing or dementia-delaying effect from zoster vaccination that is less vulnerable to confounding and bias than the existing associational evidence.

NEXT GENERATION OF VACCINOLOGISTS COMMITTEE UPDATE

This year, the **Next Generation of Vaccinologists (NextGenVacc)** committee continues to organize an engaging **monthly webinar series** designed to support early-career researchers (**ECR**s) worldwide. These sessions, with speakers from around the globe, bring together a vibrant mix of scientific innovation and professional development, strengthening our mission to create an inclusive, global platform where emerging vaccinologists can learn, connect, and grow.

Our early-career speakers showcase an impressive breadth of innovation across vaccine platforms, immunology, and delivery technologies. The 2025 ECR speaker series opened with a presentation on enhancing humoral immunogenicity of adenoviral vector vaccines through capsid display (**Alexanders Sampson**), setting an exciting tone for the year. This presentation was followed by a longitudinal analysis of human immune responses to commercial influenza vaccination (**James Allen**), offering valuable insights into real-world immunogenicity. We then explored the development of Galsomes, adjuvanted mRNA-LNPs, as a promising strategy for improving tuberculosis vaccines (**Ilke Aaernout**), before turning to the innate immune activation driven by LNP-formulated plasmid DNA and its implications for adaptive immunity (**Nicholas Tursi**). Mid-year, we delved into advances in saRNA delivery using novel PEI-inspired polymers (**Lisa Opsomer**) and examined the role of CTH522/CAF®01-

induced Th17 T cells in protection against *Chlamydia trachomatis* (**Nina Nguyen**). The series continued with a Southern African perspective on mapping B cell precursors for germline-targeting HIV vaccine strategies (**Judie Magura**), followed by an introduction to molecular clamp technology as a platform for rapid vaccine development (**Andrew Young**). We concluded the year with two compelling talks: one on COVID-19-related placental inflammation (**Yana Kumpaneko**) and its impact on fetal development in a hamster model, and another on microcapsule-based approaches for single-shot vaccination (**Romain Guyon**).

Complementing these scientific deep dives, our expert speaker series provided ECRs with invaluable guidance on navigating the broader landscape of vaccine research and development. Leaders from academia, industry, and global health shared their experiences on entrepreneurship, biotech start-ups, and the realities of establishing an academic laboratory. Attendees gained practical insights into business development, academia-industry partnerships, and the ambitious goal of delivering pandemic vaccines within 100 days. Additional sessions explored adjuvants and delivery systems, strategic consulting, conducting impactful research in under-resourced settings, and the importance of early intellectual property awareness. Discussions on building positive research cultures, transitioning between sectors, securing fellowships, and the career journey from scientific discovery to vaccine start-ups, including a memorable session on microneedle vaccination, rounded out a truly comprehensive program.

We welcomed on average over 70 attendees per webinar, with 178 in May in CEPI's presentation (**Dr. Renske Hesselink**), with many more subsequent views on the YouTube platform. Together, **these webinars create a dynamic and supportive environment for early-career vaccinologists**, fostering scientific exchange, professional growth, and global collaboration. We are grateful to all speakers and participants who contributed to making 2025 an inspiring year for the NextGenVacc community, and we look forward to continuing this momentum through 2026!

Stay tuned for next month's webinar covering next-gen and mRNA-based tuberculosis vaccines with our key speakers coming from Australia and Europe.

You can watch recordings of the webinar series on our website and follow us on our social media platforms!

https://isv-online.org/next-generation-isv-members/isv-next-generations-webinars/

UPCOMING WEBINARS

International Society for VACCINES

ISV April Webinar
8 April, 2026

Harnessing chaperones for AI/Structure-based vaccine design

Baik Lin Seong, Yonsei University, South Korea / ISV Board Member

Moderator: *Joon Haeng Rhee, Chonnam National University, South Korea*

US & Europe	South America	Africa	Asia	Australia
13:00 (PDT) 16:00 (EDT) 21:00 (BST) 22:00 (CEST)	14:00 (CST) 17:00 (ART)	21:00 (West) 22:00 (SAST) 23:00 (East)	01:30 (IST) 9 Apr 04:00 (CST) 9 Apr 05:00 (KST) 9 Apr	04:00 (AWST) 9 Apr 06:00 (AEST) 9 Apr

Wednesday, 8 April 2026

Join Webinar here:
https://zoom.us/j/96698677588

International Society for VACCINES

ISV's Virtual AI in Vaccine Development Mini-Symposium
Thursday, 23 April, 2026

09:00 – 09:25 (EDT)

Pathogen tracking: *Potential Strategic Considerations for Scientists and Industry*

Kumar Singh Saikatendu, *SVP – AI & ML, Novavax*

09:50– 10:15 (EDT)

Analytics in Action: *Machine Learning for Clinical Trial Event Rate Prediction*

Federico Fantone, *Clinical Data Science, AstraZeneca*

09:25 – 09:50 (EDT)

AI Platform Solutions to Challenges in Vaccine Development

Thomas Trolle, *Director, Bioinformatics & AI/MLP, Evaxion*

10:15 – 10:40 (EDT)

Translating AI Innovation into Regulatory Confidence:
Insights from the Model Master File Framework

Guilhem Richard, *Chief Technology Officer, EpiVax Inc.*

US & Europe	South America	Africa	Asia	Australia
06:00 (PDT) / 09:00 (EDT) 14:00 (BST) / 15:00 (CEST)	07:00 (Mexico) 10:00 (Argentina)	14:00 (West Africa) 15:00 (South Africa) 16:00 (East Africa)	18:30 (IST) 21:00 (CST) 22:00 (KST)	21:00 (AWST) 23:00 (AEST)

Zoom Link:
https://zoom.us/j/98517101650



ISV Events Calendar

2025 ISV Congress

Special Issue by HV&I

The Open Access journal Human Vaccines & Immunotherapeutics is organizing, together with Dr. Ed Rybicki, the ISV Congress special issue. HV&I has published seven special issues from the ISV Congress in the past years. We encourage you to contribute your paper and take advantage of a 15% APC discount.

Send your proposal to, and get more information from Dr. Adam Weiss (adam.c.weiss@taylorandfrancis.com) by **31 March 2026**.

ISV PAPERS OF THE MONTH

The ISV Outreach Committee Members review vaccine literature published in the last month and nominate 2-3 papers for consideration. Committee Members then vote on the nominated papers and the paper receiving the majority of votes is selected as the paper of the month.

FEBRUARY 2026 PAPER OF THE MONTH

Adenoviral Inciting Antigen and Somatic Hypermutation in VITT

N Engl J Med. 2026 Feb 12;394(7):669-683. doi: 10.1056/NEJMoa2514824. PMID: 41671482; PMCID: PMC12900036.

Authors
Wang JJ, Schönborn L, Warkentin TE, Müller L, Thiele T, Ulm L, Völker U, Ameling S, Franzenburg S, Kaderali L, Tzvetkova A, Colella A, Chataway T, Tan CW, Armour B, Troelnikov A, Rutten L, McCluskey J, Zahn R, Gordon TP, Greinacher A.

Abstract
Background: Vaccine-induced immune thrombocytopenia and thrombosis (VITT) is a rare prothrombotic complication that occurs after adenoviral vector-based vaccination against coronavirus disease 2019; in rare cases, it can also occur after natural adenovirus infection. VITT is mediated by platelet-activating antibodies against the highly cationic protein platelet factor 4 (PF4). The underlying inciting antigen trigger and immunopathogenesis remain unknown.

Methods: We used antibody proteomics to determine the amino acid sequences of anti-PF4 antibodies from 21 patients with VITT and sequenced the genes encoding the immunoglobulin light-chain hypervariable region from 100 patients with VITT. To identify an adenoviral trigger, we used the antigen-binding fingerprints of anti-PF4 and anti-adenovirus protein antibodies to identify a shared serum clonotype and subsequently used adenovirus protein peptides and recombinant anti-PF4 VITT antibodies to map the mimicking linear epitope.

Results: Genomic and proteomic profiling of VITT antibodies revealed a shared immunoglobulin light-chain allele, IGLV3-21*02 or *03, harboring a critical somatic hypermutation, K31E. Only antibodies purified against adenoviral core protein VII (pVII) contained anti-PF4 species matching the VITT fingerprint; antibodies against intact virions or other adenoviral proteins did not. Cross-reactive IgGs were mapped to a basic linear epitope on pVII. A pathogenic anti-PF4 VITT antibody, back-mutated to germline (K31), lost its prothrombotic activity in vitro and in vivo and preferentially bound pVII, a finding that directly supported the role of the hypermutation in the antigenic shift from adenovirus pVII to PF4.

Conclusions: The results of our study indicate that VITT occurs when, in persons with immunoglobulin light-chain allele IGLV3-21*02 or *03, a specific somatic hypermutation develops that affects antibodies that recognize a specific epitope on the adenoviral core protein pVII, which results in misdirection of antibody targeting toward PF4. (Funded by Deutsche Forschungsgemeinschaft and others; German Clinical Trials Register number, DRKS00025738; EU Post-Authorization Study Register number, EUPAS45098.).

MARCH 2026 PAPER OF THE MONTH

DNA origami vaccine nanoparticles improve humoral and cellular immune responses to infectious diseases.

Nat Biomed Eng. 2026 Mar 11. doi: 10.1038/s41551-026-01614-w. Epub ahead of print. PMID: 41813804.

Authors
Zeng YC, Young OJ, Xiong Q, Si L, Ku MW, Bernier SG, Dembele H, Isinelli G, Gilboa T, Swank Z, Seok SH, Rajwar A, Jiang A, Zhai Y, Williams LD, Hellman CA, Wintersinger CM, Graveline AR, Vernet A, Sanchez M, Bardales S, Tomaras GD, Ryu JH, Kwon IC, Goyal G, Ingber DE, Shih WM.

Abstract
Current SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2) vaccines have shown robust induction of neutralizing antibodies and $CD4^+$ T cell activation; however, $CD8^+$ responses are variable, and the duration of immunity and protection against variants are limited. Here we repurpose our DNA origami vaccine nanotechnology DoriVac to target infectious viruses, namely, SARS-CoV-2, HIV and Ebola. The DNA origami nanoparticle, conjugated with infectious-disease-specific heptad repeat 2 peptides, which act as highly conserved antigens, and CpG adjuvant at precise nanoscale spacing, induces neutralizing antibodies, Th1 $CD4^+$ T cells and $CD8^+$ T cells in naive mice, with significant improvement over a bolus control. Pre-clinical studies using lymph-node-on-a-chip systems validate that DoriVac, when conjugated with antigenic peptides or proteins, induces promising cellular and humoral immune responses in human cells. Moreover, DoriVac bearing full-length SARS-CoV-2 spike protein achieves immune responses comparable to current mRNA vaccine platforms while potentially reducing storage constraints. These results suggest that DoriVac holds potential as a versatile, modular vaccine platform, capable of inducing both humoral and cellular immunities, underscoring its potential future use.

ISV NEW MEMBERS

Basiru	Aliyu	Marianne	Mureithi
Aleksandar	Antanasijevic	Svearike	Oeverdieck
Salome	Chira	Eva	Rogelj
Mariana	Colaço	Anindita	Sengupta
William	Duprex	Nura	Shuaib
Valentina	Eberlein	Asuka	Tobuse
Willem	Hanekom	Andani	Tshiitamune
Omari	Hassan	Gulbuse	Turan
Charles	Ibeneme	Samuel	Valdebenito
Henrik	Johansson	Vera	Viherlehto
Qingsheng	Li	Manjeet	Yadav

Kaiwen Liu

To apply for the ISV Member benefit of a 15% discount to the Article Publishing Charge for the open access journal, Human Vaccines and Immunotherapeutics, contact info@isv-online.org to be provided with the guide and instructions. (A 50% discount is applicable to scientists from lower-middle-income countries; researchers from low-income countries are eligible for a full waiver (100% discount).

Stay Engaged with the ISV through its Social Media Channels:

ISV on LinkedIn

ISV on Facebook

ISV on Instagram

ISV on X

ISV on Bluesky

THANK YOU TO OUR PARTNERS & SPONSORS

PARTNER

International Vaccine Institute

National Research Council Canada

CEPI

International Veterinary Vaccinology Network

GF

Afrigen Biologics & Vaccines
An Avacare Health & IDC Company

PRF
Poliomyelitis Research Foundation

IMPERIAL

BIOVAC
science of protecting life

aspen
HOLDINGS

medicines patent pool

DIAMOND

sanofi

GOLD

Pfizer

AstraZeneca

vaxxas

BAVARIAN NORDIC

GPN VACCINES

eubiologics

VISMEDERI
ANALYSES FOR LIFE IMPROVEMENT

SILVER

MABTECH

ARCTURUS therapeutics

moderna

GC Biopharma

INOVIO

human VACCINES & IMMUNOTHERAPEUTICS

Intravacc.
Innovating your vaccines

Hilleman Laboratories

EXPERT REVIEW OF VACCINES

OTHER SUPPORT

BLUE LAKE BIOTECHNOLOGY

DIAGNOSTECH

SARTORIUS